Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study

George Pentheroudakis(Hellenic Cooperative Oncology Group), Nikolaos Pavlidis(University Hospital of Ioannina), Aristotelis Bamias(National and Kapodistrian University of Athens), Nikolaos I. Xiros(University General Hospital Attikon), Haralabos P. Kalofonos(University of Patras), E. Samantas(Hospital Agioi Anargyroi), Maria Karina(Aristotle University of Thessaloniki), George Samelis(Hippocration General Hospital), Theofanis Economopoulos(University General Hospital Attikon), A. Koutras(General University Hospital of Patras), Evangelos Briasoulis
Acta Oncologica
January 1, 2008
10.1080/02841860701843043
Cited by 34

Related Papers

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2020|786
High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2014|760
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
|Annals of Oncology|2017|591